TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12650785
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg every 8 hours for 2 weeks
Study: 11242715
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with Lansoprazole (30 mg once a day), Amoxycillin (500 mg three times a day), and Roxythromycin (150 mg twice a day)
Study: 11242715
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with Lansoprazole (30 mg once a day) and Amoxycillin (500 mg three times a day)
Study: 1387500
Drug: Captopril 1
Normalized name: captopril 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 1 x 25 mg
Study: 1387500
Drug: Ramipril 1
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 1 x 2.5 mg
Study: 24485487
Drug: 1μg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1μg of cosyntropin administered intravenously
Study: 22894958
Drug: CYD-TDV (tetravalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD-TDV (tetravalent dengue vaccine)
Study: 22894958
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (placebo for first dose, licensed hepatitis-A for children, influenza vaccine for adolescents and adults)
Study: 17662087
Drug: Dronedarone 400
Normalized name: dronedarone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone 400 mg twice daily for 7 days
Study: 12038948
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of cevimeline 3 times daily
Study: 8529717
Drug: Covert monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Covert monitoring of inhalation
Study: 8529717
Drug: Theophylline treatment
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline treatment (open randomized trial)
Study: 8529717
Drug: Physician prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician prescribed doses of theophylline
Study: 19639058
Drug: rhPDGF-BB (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhPDGF-BB (0.3 mg/mL) with freeze-dried bone allograft (FDBA; group A)
Study: 19639058
Drug: rhPDGF-BB (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhPDGF-BB (0.3 mg/mL) with anorganic bovine bone graft (ABBG; group B)
Study: 19639058
Drug: rhPDGF-BB (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhPDGF-BB (0.3 mg/mL) with anorganic bovine bone graft/mineralized collagen bone substitute (ABBG/MCBS; group C)
Study: 17371357
Drug: Lamotrigine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (50 mg)
Study: 11576883
Drug: 4 microg
Normalized name: Paricalcitol 4 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 microg of paricalcitol intravenously with the hemodialysis session three times weekly for 12 weeks
Study: 9305517
Drug: Biological markers
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological markers using neuroimaging or other measures
Study: 7870844
Drug: MCPP (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCPP (0.5 mg/kg)
Study: 2680231
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of [1-13C]leucine (0.05 g/kg)
Study: 2680231
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of unlabelled leucine (4 g)
Study: 21474474
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg before operation and 75 mg twice daily for 5 days)
Study: 16272755
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (specific drugs not mentioned)
Study: 10550466
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day alendronate
Study: 10550466
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day alendronate
Study: 2081141
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 40 mg
Study: 2081141
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 20 mg and 40 mg
Study: 2081141
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 10 mg, 20 mg, and 40 mg
Study: 120549
Drug: Deanol (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deanol (900 mg/day for 21 days)
Study: 11159568
Drug: Agnus castus
Normalized name: Vitex agnus-castus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agnus castus (dry extract tablets) one tablet daily for three consecutive cycles
Study: 11159568
Drug: Agnus castus
Normalized name: Vitex agnus-castus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agnus castus (dry extract tablets)
Study: 31209718
Drug: Clinical medication
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical medication review (CMR)
Study: 22613545
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg/d and 300 mg/d
Study: 20434961
Drug: 900 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/d of DHA orally for 24 weeks
Study: 10208225
Drug: Betaxolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol (20 mg daily)
Study: 7842188
Drug: Ethacrynic acid
Normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethacrynic acid 25 mg
Study: 7842188
Drug: Ethacrynic acid
Normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethacrynic acid 50 mg
Study: 2220345
Drug: Bromocriptine 2.5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5 mg twice daily for 2 weeks
Study: 2220345
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets 1 tablet twice daily for 2 weeks
Study: 28432894
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) treatment for OCD, PD/A, SAD, and GAD
Study: 22192583
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (50 g daily)
Study: 14674905
Drug: Five times
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five times weekly application of short-contact dithranol (SCD)
Study: 14674905
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times weekly application of short-contact dithranol (SCD)
Study: 10505482
Drug: Sulpiride (150‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (150‐300 mg)
Study: 9069860
Drug: Acupressure (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure (treatment group, n = 30) with bilateral elastic bands exerting pressure on the wrist during the perioperative period.
Study: 6187310
Drug: High-dose gestagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose gestagen therapy
Study: 6187310
Drug: Chemotherapy (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cyclophosphamide, 5-fluorouracil, methotrexate, vinblastine)
Study: 28131423
Drug: Preoperative use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative use of angiotensin receptor blockers (ARBs)
Study: 28131423
Drug: No renin-angiotensin-system
Approvals — FDA: no, EMA: no, PMDA: no
Description: No renin-angiotensin-system inhibitors
Study: 28131423
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors (ACEis)
Study: 12527544
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy for generalized anxiety disorder in primary care (CBT‐GAD/PC)
Study: 10664917
Drug: Celecoxib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (600 mg bid)
Study: 9769898
Drug: Fast release
Normalized name: Delsym Cough Maximum Strength Fast Release Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast release tablet (FR 100 mg) at 8 a.m. and 8 p.m. and 1 p.m.
Study: 9769898
Drug: Fast-slow release
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-slow release tablet (FSR 150 mg) at 8 a.m. and 8 p.m. and 1 p.m.
Study: 9769898
Drug: Intramuscular solution
Normalized name: Intramuscular Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular solution (i.m. 100 mg) at 8 a.m. and 8 p.m. and 1 p.m.
Study: 9769898
Drug: Fast release
Normalized name: Delsym Cough Maximum Strength Fast Release Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast release tablet (FR 100 mg) vs Fast-slow release tablet (FSR 150 mg)
Study: 3294190
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (30-90 mg daily)
Study: 3294190
Drug: Indoramin (75-225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (75-225 mg daily)
Study: 21929768
Drug: Vigorous Intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigorous Intensity High Dose Exercise Augmentation (DEI)
Study: 21929768
Drug: Health Education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health Education Intervention Augmentation (HEI)
Study: 18356552
Drug: B‐vitamins (folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: B‐vitamins (folic acid 2 mg, vitamin B6 25 mg, and vitamin B12 0.5 mg)
Study: 17162709
Drug: Intranasal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal E2 (n = 16)
Study: 1964962
Drug: Thiotepa and
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thiotepa and Etoposide (total dose: Thiotepa 600-900 mg/M2 over 3 days, Etoposide 1500 mg/M2 over 3 days)
Study: 1964962
Drug: Thiotepa, Etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiotepa, Etoposide and BCNU (total dose: BCNU 600 mg/M2 over 4 days)
Study: 504040
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 650 mg (Control)
Study: 6393443
Drug: B-diet plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-diet plus 3 X 20 g fresh onion per day
Study: 6393443
Drug: B-diet plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-diet plus 3 X 200 g green beans per day
Study: 26638911
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of resveratrol plus 10 mg of piperine
Study: 22045316
Drug: DHEA (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (130 mg)
Study: 10094425
Drug: Standard monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard monotherapy (Carbamazepine or Phenytoin)
Study: 2347116
Drug: Low alcohol
Normalized name: Low alcohol beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low alcohol beer (reduced weekly alcohol intake from 481 +/- 47 mL to 52 +/- 5 mL)
Study: 31980448
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of azathioprine (AZA) to second anti-TNF therapy
Study: 31980448
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with second anti-TNF (no AZA)
Study: 30431709
Drug: Bioabsorbable steroid-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioabsorbable steroid-releasing implants (mometasone furoate, 370 μg)
Study: 30431709
Drug: Control (contralateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (contralateral side without implant)
Study: 30026614
Drug: Brief Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Behavioral Therapy for Cancer-related Insomnia (BBT-CI)
Study: 20617484
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training (CG, n=8)
Study: 17975981
Drug: Vinblastine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine (2 mg/m2, IV, q 1 wk)
Study: 12425728
Drug: Phytosterol-enriched chocolate
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol-enriched chocolate (1.8 g unesterified phytosterols/d)
Study: 7540058
Drug: High-dose magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose magnesium regimen (4.2 +/- 0.7 g magnesium sulfate before bypass, followed by 11.9 +/- 2.8 g magnesium chloride until the first postoperative morning, and 5.5 +/- 1.0 g until the second postoperative morning)
Study: 7540058
Drug: Low-dose magnesium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose magnesium regimen (2.9 +/- 0.5 g magnesium sulfate at the first postoperative morning, and 1.4 +/- 0.1 g at the second postoperative morning)
Study: 29920521
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLL) applied at auriculotherapy points
Study: 29920521
Drug: Simulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulation of LLL treatment (control group)
Study: 27431736
Drug: IB1 topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: IB1 topical protective lotion
Study: 28817997
Drug: Cladribine 5.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine 5.25 mg/kg
Study: 22017519
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets (both doses)
Study: 17261234
Drug: Antibiotic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapies based on stratification by disease severity
Study: 17261234
Drug: Antibiotic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapies utilized in the trial (specific antibiotics not mentioned)
Study: 11255901
Drug: Immediate prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate prescription (92 patients)
Study: 11255901
Drug: Delayed prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed prescription (99 patients)
Study: 9734940
Drug: 30 IU/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 IU/m2 somatropin per week as daily subcutaneous injections
Study: 9734940
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (non-consent group)
Study: 28926855
Drug: Once-daily Fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily Fluticasone Furoate/Vilanterole (FF/VI) 200/25 µg via ElliptaTM DPI
Study: 28926855
Drug: Twice-daily Fluticasone
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily Fluticasone Propionate/Salmeterol (FP/SAL) 500/50 µg via DiskusTM DPI
Study: 12871541
Drug: Antidote administration
Normalized name: thiosulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidote administration (specific antidotes)
Study: 12871541
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K administration
Study: 10692930
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin (2 drops of 0.3% ophthalmic solution every 30 min for 3 h, then every 60 min for the next 3 h)
Study: 10692930
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (single dose of 1000 mg 6 h before surgery)
Study: 8836872
Drug: Beta-carotene (31.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (31.4 mg/day) plus D-alpha-tocopherol acetate (720 IU/day) supplements
Study: 8354735
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in maintenance therapy)
Study: 26909786
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) + Total Intravenous Anesthesia (TIVA)
Study: 21055963
Drug: Standard COP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard COP group (0.5 g/kg albumin in priming, COP target at 15 mmHg)
Study: 16567158
Drug: TV group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV group (children who watched more daily hours of TV)
Study: 12627041
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/day for 21 days)
Study: 10689253
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of contrast (1.3 mL in 50 mL normal saline initially at 4.0 mL/min)
Study: 10689253
Drug: Bolus injections
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injections of contrast (10 microL/kg each over a period of 30 to 60 seconds)
Study: 7503004
Drug: Oral propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propafenone 600 mg
Study: 2032708
Drug: Miconazole therapy
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole therapy
Study: 2032708
Drug: Oral nystan
Normalized name: nystatin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nystan
Study: 2032708
Drug: Oral yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral yeast carriage rate in women
Study: 30427246
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (BRJ) 140 mL daily (∼800 mg/d nitrate)
Study: 23466709
Drug: S boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: S boulardii (1 g/day)
Study: 11376827
Drug: enalapril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (10-20 mg per day)
Study: 11376827
Drug: losartan (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan (50-100 mg per day)
Study: 9401542
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment at a dose of 0.1 IU/kg/day for 2 years (group A)
Study: 9401542
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment at a dose of 0.2 IU/kg/day for the second year (group B)
Study: 28325123
Drug: 5% menthol
Normalized name: MENTHOL 5 g TOPICAL PATCH [Cold Hot Medicated Patch 5% Menthol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% menthol gel applied to the skin over the quadriceps muscle
Study: 16575035
Drug: Betamethasone 8
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 8 mg iv
Study: 16575035
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 mL (placebo)
Study: 1525903
Drug: Anxiolytics and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiolytics and Mg-lactate
Study: 3897612
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg of S6472 given orally before a meal
Study: 3897612
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg of S6472 given orally after a light meal
Study: 3897612
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg of S6472 given orally after a usual meal
Study: 3897612
Drug: 750 to
Normalized name: benzalkonium chloride 1:750 TOPICAL TINCTURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 to 1,500 mg/day of S6472
Study: 26655188
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pharmacological agents)
Study: 10456621
Drug: Low fixed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fixed dose of warfarin (1.25 mg/day) for an additional month (group B)
Study: 2404052
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose simvastatin
Study: 2404052
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose simvastatin
Study: 10404843
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 to 40 mg)
Study: 856370
Drug: Self-administered questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaire on chest pain and intermittent claudication
Study: 31007215
Drug: Topical Tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Tacrolimus 0.03% ointment
Study: 31007215
Drug: Topical Dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Dexamethasone 0.05% ointment
Study: 23559402
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral dose of olanzapine
Study: 19220279
Drug: Cetilistat 50
Normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cetilistat 50 mg t.i.d. (n = 7)
Study: 19220279
Drug: Cetilistat 60
Normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cetilistat 60 mg t.i.d. (n = 9)
Study: 19220279
Drug: Cetilistat 100
Normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cetilistat 100 mg t.i.d. (n = 7)
Study: 19220279
Drug: Cetilistat 120
Normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cetilistat 120 mg t.i.d. (n = 9)
Study: 19220279
Drug: Cetilistat 150
Normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cetilistat 150 mg t.i.d. (n = 16)
Study: 19220279
Drug: Cetilistat 240
Normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cetilistat 240 mg t.i.d. (n = 9)